You are here

Eradicating PSCs with DHODH Inhibitors

The success of regenerative medicine approaches that employ pluripotent stem cells (PSCs) requires the exclusion of self-renewing undifferentiated cells from the differentiated cell population. Now, a new study from Toru Kondo (Hokkaido University, Japan) describes how brequinar (BRQ), the most potent available inhibitor of dihydroorotate dehydrogenase (DHODH), specifically induces elevated levels of cytotoxicity in mouse PSCs and not lineage‐committed progenitor cells and differentiated functional cells. Furthermore, BRQ prevents teratoma formation in vivo without any visible unwanted side effects in mice. For all the details, see STEM CELLS now!